16:08 EDT Palisade Bio (PALI) files to sell 8.9M shares of common stock for holders
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PALI:
- Palisade Bio’s Strategic Positioning and Promising Trial Results Earn Buy Rating
- Palisade Bio’s PALI-2108: A Promising New Treatment for Ulcerative Colitis
- Palisade Bio announces new data from ongoing program evaluating PALI-2108
- Palisade Bio receives notice of allowance for patent of PALI-2108 in China
- Palisade Bio’s Phase 1 Study on PALI-2108: A New Hope for Ulcerative Colitis Treatment